Antibacterial; broad-spectrum serine beta-lactamase Inhibior.

Targets PD-L1 protein; in phase 1 clinical trials (2014).

NCI: A Fc optimized monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; B7 homolog 1; B7H1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, durvalumab binds to PD-L1, thereby blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells. This may reverse T-cell inactivation and activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against PD-L1-expressing tumor cells. PD-L1, a member of the B7 protein superfamily, is overexpressed on certain tumor cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. The Fc region of durvalumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). (NCI Thesaurus)

Constituent of the essential oil of Cyclorhiza waltonii.

A dual IGF-I/II neutralizing antibody for treatment of advanced solid tumours.

A 367 amino acid protein of predicted MW 39369 Da; has multi-enzyme [Protein-tyrosine-phosphatase (EC 3.1.3.48) and Phosphoprotein phosphatase (EC 3.1.3.16 )] activities; coded by an immediate early gene; may have a role in mediating the G0/G1 transition; bears sequence motif which defines the family of protein-tyrosine phosphatases; GenBank AF026522 (Gallus gallus); RefSeq NM_013642 (mouse), NM_004417 (human), NM_053769 (rat).

TSCA Definition 2019: The dust generated from the initial cleaning of off gases from a blast furnace. Composed primarily of iron and carbon. May contain varying amounts of other elements, oxides, and trace compounds.

TSCA Definition 2019: Dust generated during the making, breaking and handling of sinter which is recovered through the use of pollution abatement equipment.